Literature DB >> 29637528

Author Correction to: Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease.

Lawrence W Elmer1, Jorge L Juncos2, Carlos Singer3, Daniel D Truong4, Susan R Criswell5, Sotirios Parashos6, Larissa Felt7, Reed Johnson7, Rajiv Patni7.   

Abstract

An Online First version of this article was made available online at http://link.springer.com/journal/40263/onlineFirst/page/1 on 12 March 2018. An error was subsequently identified in the article, and the following correction should be noted.

Entities:  

Year:  2018        PMID： 29637528      PMCID： PMC6828147          DOI： 10.1007/s40263-018-0510-z

Source DB:  PubMed          Journal:  CNS Drugs        ISSN： 1172-7047            Impact factor:   5.749


  2 in total

1.  EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease.

Authors:  Caroline M Tanner; Rajesh Pahwa; Robert A Hauser; Wolfgang H Oertel; Stuart H Isaacson; Joseph Jankovic; Reed Johnson; Dustin Chernick; Jean Hubble
Journal:  J Parkinsons Dis       Date:  2020       Impact factor: 5.568

2.  Effects of Gocovri (Amantadine) Extended-Release Capsules on Motor Aspects of Experiences of Daily Living in People with Parkinson's Disease and Dyskinesia.

Authors:  Robert A Hauser; Shyamal H Mehta; Daniel Kremens; Dustin Chernick; Andrea E Formella
Journal:  Neurol Ther       Date:  2021-05-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.